CJC-1295 No DAC 10MG

CJC-1295 10mg is a synthetic research peptide and growth hormone–releasing hormone (GHRH) analog, widely studied for its ability to enhance and prolong endogenous growth hormone secretion. In laboratory research settings, CJC-1295 is of interest for investigations into growth hormone signaling, metabolic regulation, and endocrine pathway dynamics, making it a valuable compound in hormone-focused research.

For laboratory research use only. Not intended for human or animal consumption.

Guaranteed Safe Checkout
Extra Features
  • Premium Quality
  • Secure Payments
  • Satisfaction Guarantee
  • Worldwide Shipping
  • Money Back Guarantee
CTA

For Research Use Only. Not for Human Use.

CJC-1295 with DAC (Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Lys(Maleimidopropionyl)-NH₂) is a modified analog of growth hormone-releasing hormone (GHRH 1-29) featuring a Drug Affinity Complex (DAC) attached via a lysine linker at position 30, enabling strong binding to serum albumin for an extended half-life of 5–8 days. This allows sustained, pulsatile GH secretion without the rapid degradation of native GHRH, making it a subject of interest in neuroendocrine research. Developed by ConjuChem Biotechnologies in the mid-2000s, it advanced to Phase II clinical trials before discontinuation due to manufacturing issues. This research-grade lyophilized powder is synthesized under strict quality controls and includes full analytical documentation, making it suitable for in vitro and preclinical research applications.

Key Scientific Attributes

  • High-purity CJC-1295 with DAC (≥99% by HPLC/MS, acetate salt form)
  • Verified 30-amino-acid sequence with DAC modification for albumin bioconjugation
  • Lyophilized formulation for enhanced long-term stability (up to 3 years at -4°F)
  • Full Certificate of Analysis (COA) with HPLC, MS, amino acid analysis, and endotoxin testing (<0.001 EU/mg)
  • Manufactured in GMP-aligned, ISO-compliant facilities
  • Suitable for receptor-binding, pharmacokinetic, and pituitary signaling studies

Research-Referenced Attributes (Based on scientific literature; not intended as therapeutic claims.)

  • Retains native pulsatile GH secretion profile relative to unmodified GHRH analogs in preclinical models
  • Subject of preclinical investigations into neuroendocrine signaling and pituitary axis dynamics
  • Pharmacokinetic profile characterized by extended albumin binding and reduced clearance rate
  • Relevant to in vitro and preclinical studies of endocrine pathway modeling

Why Researchers Choose CJC-1295 with DAC

  • Exact clinical-sequence match with DAC modification for authentic pharmacokinetics
  • Third-party verified purity (>99%) and no fillers (e.g., mannitol-free)
  • Transparent documentation (HPLC/MS COA, endotoxin-free)
  • Suitable for use in endocrinology, neuroendocrine, and pituitary biology research settings
  • Competitive research pricing with bulk options
Product Name

CJC-1295 peptide

Avg Purity

≥99%

CAS Number

863288-34-0

Molecular Formula

C₁₆₅H₂₆₉N₄₇O₄₆

Molecular Weight

Approximately 3647.2 Da

Peptide Structure

Modified 30-amino-acid GHRH analog containing a Drug Affinity Complex